RedHill Biopharma (RDHL) Operating Leases (2019 - 2025)

RedHill Biopharma (RDHL) has 7 years of Operating Leases data on file, last reported at $900000.0 in Q4 2025.

• Operating Leases for Q4 2025 came in at $900000.0, up 29900.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $900000.0 (up 29900.0% YoY), and the FY2025 annual result was $900000.0, up 29900.0% from the prior year.
• Operating Leases rose to $900000.0 in Q4 2025 per RDHL's latest filing, from $3000.0 in the prior quarter.
• Over five years, Operating Leases peaked at $6.4 million in Q4 2022 and troughed at $3000.0 in Q4 2024.
• A 5-year average of $2.1 million and a median of $900000.0 in 2025 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2024 and 2025: Operating Leases slumped 99.34% in 2024, then surged 29900.0% in 2025.
• A 5-year view of Operating Leases shows it stood at $2.6 million in 2021, then jumped by 150.31% to $6.4 million in 2022, then slumped by 92.94% to $455000.0 in 2023, then tumbled by 99.34% to $3000.0 in 2024, then surged by 29900.0% to $900000.0 in 2025.
• Business Quant data shows RDHL's Operating Leases at $900000.0 in Q4 2025, $3000.0 in Q4 2024, and $455000.0 in Q4 2023.